

PerkinElmer launches industry-first ready-to-use viral vector assays

22 November 2022 | News

Streamlined workflows aim to shorten research and development for novel therapies to combat diseases like cancer and Alzheimer's



PerkinElmer, Inc. has launched ready-to-use Adeno-associated Virus Vectors (AAV) Detection Kits to support researchers working on gene therapies for a variety of serious diseases. The high-throughput viral assays are designed to help researchers quickly and easily characterize viral vector particles being produced to enable decision-making for safe and efficient gene transfer.

The validated and fully automatable assays are built on PerkinElmer's proprietary AlphaLISA technology which requires no separation and are the only optimised, no-wash AAV detection assays currently available on the market. The new offering provides researchers expanded options to measure viral titers beyond ELISA and other wash-based systems, which can be time-consuming and limited in assay range.

Designed to streamline gene therapy research and development workflows with an easier-to-use and more high throughput method, each of the seven kits detects specific serotypes to target different cell types in the body for gene therapy application.

The AAV assays expand PerkinElmer's cell and gene therapy portfolio which also includes gene editing and modulation, cell counting, antibody and flow cytometry innovations. They also further propel the company's ability to provide researchers with end-to-end workflow solutions from early-stage discovery through later stage research and development.